Ernexa Therapeutics has finished process development for its lead cell therapy and moved into GMP manufacturing. The company, which trades on Nasdaq as ERNA, said on May 27 that it still plans to file an Investigational New Drug application for ERNA-101 in the third quarter of 2026.
Technology transfer for the product is also under way. Chief executive Sanjeev Luther said completing process development and moving into GMP production are “critical steps toward IND clearance.” He said the company is “executing against our development strategy with urgency and discipline.” Luther also described Ernexa as “entering a transformational phase” and said the company hopes ERNA-101 can “bring new hope to patients and families in need of better therapeutic options.”
What the therapy is
Ernexa engineers induced pluripotent stem cells and turns them into induced mesenchymal stem cells, or iMSCs. The cells come from a donor source rather than the patient, so nobody has to harvest and modify a patient’s own cells. Ernexa calls the result a scalable, off-the-shelf treatment.
ERNA-101 is built to activate and steer the immune system so it recognizes and attacks cancer cells. The company’s first target is ovarian cancer. A second product, ERNA-201, is aimed at inflammation and autoimmune disease.
Preclinical data from a syngeneic ovarian cancer model, reported in April, gave the company some of its strongest early support. ERNA-101 combined with PD-1 blockade produced deep and lasting tumor regressions and longer survival, and it did better than either treatment alone. Clinical Trial Vanguard, which covered the results, noted that they were nonclinical and came without disclosed effect sizes. The idea behind the combination is to turn immunologically cold tumors into ones that respond to treatment.
The road to the clinic
Ernexa has laid out a sequence. After the IND filing, a first-in-human Phase 1 trial in platinum-resistant ovarian cancer is planned for the fourth quarter of 2026. The company has already held a pre-IND meeting for ERNA-101. It is guiding to a first clinical readout in the first half of 2027 and a possible Phase 2 move with a partner in the second half of that year. For ERNA-201, a pre-IND meeting is targeted for the fourth quarter of 2026.
Money is part of the story. Ernexa cut general and administrative costs by 61% year over year to conserve cash, and a recent $10.5 million financing is expected to cover the near-term milestones. Clinical Trial Vanguard judged that the raise looks sized to reach IND filing and early trial start, not to carry the program through the 2027 readout.
The same outlet listed what to watch next: first GMP batch release, the toxicology and biodistribution package behind the IND, the choice of PD-1 partner, and the design of the first trial, including whether it opens with combination therapy.
Sources
- Ernexa Therapeutics Successfully Completes Key Manufacturing and IND Preparation Milestones for ERNA-101 Toward First-in-Human Clinical Development
- Ernexa Therapeutics Advances Toward 2026 Human Trials
